The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
The fibrosis marker galectin‐3 and outcome in the general population
Open accessAbstract
de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJL, van der Harst P (University of Groningen). The fibrosis marker galectin‐3 and outcome in the general population. J Intern Med 2012; 272: 55–64. Objective. Galectin‐3 is involved in fibrosis and inflammation and plays a role in heart failure, renal disease, obesity and cancer. We aimed to establish the relationship between galectin‐3 and cardiovascular (CV) risk factors and mortality in the general population. Design and subjects. This study included 7968 subjects from the Prevention of REnal and Vascular ENd‐stage Disease (PREVEND) cohort, with a median follow‐up of approximately 10 years. Plasma galectin‐3 was measured in baseline samples. Main outcome measures. We investigated the relationships between galectin‐3 levels, demographic characteristics and risk factors of CV disease. We determined the prognostic value for all‐cause, CV and cancer mortality. Results. The mean age of the population was 50 ± 13 years. Mean blood pressure was 129/74 mmHg, mean cholesterol was 5.7 ± 1.1 mmol L−1 and median galectin‐3 was 10.9 ng mL−1 [interquartile range (IQR) 9.0–13.1]. Galectin‐3 levels correlated with a wide range of risk factors of CV disease, including blood pressure, serum lipids, body mass index, renal function and N‐terminal pro‐B‐type natriuretic peptide (P < 0.0001). We observed a strong association between galectin‐3 and age. Furthermore, we found a gender interaction, with female subjects (n = 4001) having higher median galectin‐3 levels (11.0 ng mL−1, IQR 9.1–13.4 vs. men (n = 3967) 10.7 ng mL−1, IQR 8.9–12.8; P < 0.0001), and galectin‐3 levels in women more strongly correlated with risk factors of CV disease. After correction for the classical CV risk factors (smoking, blood pressure, cholesterol and diabetes), galectin‐3 levels independently predicted all‐cause mortality (hazard ratio per SD galectin‐3 1.09, 95% CI 1.01–1.19; P = 0.036), but not CV and cancer mortality separately. Conclusions. Galectin‐3 is associated with age and risk factors of CV disease, with a strong gender interaction for these correlations. Galectin‐3 predicts all‐cause mortality in the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors/Task Force Members, Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,512
Self-citationGalectin-3: An open-ended story
Dumic, J., Dabelic, S., & Flögel, M. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.12.020 · Cited by 1,169
Sharma, U. C., Pokharel, S., van Brakel, T. J., van Berlo, J. H., Cleutjens, J. P. M., Schroen, B., André, S., Crijns, H. J. G. M., Gabius, H. J., Maessen, J., et al. (2004) · Circulation · doi:10.1161/01.cir.0000147181.65298.4d · Cited by 947
Galectins: structure, function and therapeutic potential
Yang, R.-Y., Rabinovich, G. A., & Liu, F.-T. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000719 · Cited by 862
Hillege, H. L., Janssen, W. M. T., Bak, A. A. A., Diercks, G. F. H., Grobbee, D. E., Crijns, H. J. G. M., Van Gilst, W. H., De Zeeuw, D., De Jong, P. E., & FOR THE PREVEND STUDY GROUP (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00833.x · Cited by 629
Self-citationGalectin-3 regulates myofibroblast activation and hepatic fibrosis
Henderson, N. C., Mackinnon, A. C., Farnworth, S. L., Poirier, F., Russo, F. P., Iredale, J. P., Haslett, C., Simpson, K. J., & Sethi, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511167103 · Cited by 625
de Boer, R. A., Lok, D. J. A., Jaarsma, T., van der Meer, P., Voors, A. A., Hillege, H. L., & van Veldhuisen, D. J. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.538080 · Cited by 592
Self-citationvan Kimmenade, R. R., Januzzi, J. L., Ellinor, P. T., Sharma, U. C., Bakker, J. A., Low, A. F., Martinez, A., Crijns, H. J., MacRae, C. A., Menheere, P. P., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.061 · Cited by 567
Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal Fibrosis
Henderson, N. C., Mackinnon, A. C., Farnworth, S. L., Kipari, T., Haslett, C., Iredale, J. P., Liu, F.-T., Hughes, J., & Sethi, T. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070726 · Cited by 562
Galectin-3: A Novel Mediator of Heart Failure Development and Progression
de Boer, R. A., Voors, A. A., Muntendam, P., van Gilst, W. H., & van Veldhuisen, D. J. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp097 · Cited by 524
Self-citationThe regulation of inflammation by galectin‐3
Henderson, N. C., & Sethi, T. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00794.x · Cited by 522
Gene Expression in Fibroblasts and Fibrosis: Involvement in Cardiac Hypertrophy
Manabe, I., Shindo, T., & Nagai, R. (2002) · Circulation Research · doi:10.1161/01.res.0000046452.67724.b8 · Cited by 512
Lok, D. J. A., Van Der Meer, P., de la Porte, P. W. B.-A., Lipsic, E., Van Wijngaarden, J., Hillege, H. L., & van Veldhuisen, D. J. (2010) · Clinical Research in Cardiology · doi:10.1007/s00392-010-0125-y · Cited by 465
Self-citationSex-Related Differences in Myocardial Remodeling
Piro, M., Della Bona, R., Abbate, A., Biasucci, L. M., & Crea, F. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.065 · Cited by 329
Takenaka, Y., Fukumori, T., & Raz, A. (2002) · Glycoconjugate Journal · doi:10.1023/b:glyc.0000014084.01324.15 · Cited by 321
The extracellular matrix: At the center of it all
Bowers, S. L. K., Banerjee, I., & Baudino, T. A. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.08.024 · Cited by 277
Liu, Y.-H., D'Ambrosio, M., Liao, T.-D., Peng, H., Rhaleb, N.-E., Sharma, U., André, S., Gabius, H.-J., & Carretero, O. A. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00747.2008 · Cited by 269
Renal tubulointerstitial fibrosis: common but never simple
Hewitson, T. D. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90521.2008 · Cited by 246
Weigert, J., Neumeier, M., Wanninger, J., Bauer, S., Farkas, S., Scherer, M. N., Schnitzbauer, A., Schäffler, A., Aslanidis, C., Schölmerich, J., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1619 · Cited by 198
Chauhan, D., Li, G., Podar, K., Hideshima, T., Neri, P., He, D., Mitsiades, N., Richardson, P., Chang, Y., Schindler, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0163 · Cited by 164
Diagnostic Utility of Galectin-3 in Thyroid Cancer
Chiu, C. G., Strugnell, S. S., Griffith, O. L., Jones, S. J. M., Gown, A. M., WALKER, B. A. M., Nabi, I. R., & Wiseman, S. M. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090353 · Cited by 158
Multi-center determination of galectin-3 assay performance characteristics:
Christenson, R. H., Duh, S., Wu, A. H. B., Smith, A. A., Ábel, G., deFilippi, C. R., Wang, S., Adourian, A. S., Adiletto, C., & Gardiner, P. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.02.001 · Cited by 147
Linssen, G. C. M., Bakker, S. J. L., Voors, A. A., Gansevoort, R. T., Hillege, H. L., de Jong, P. E., van Veldhuisen, D. J., Gans, R. O. B., & de Zeeuw, D. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp420 · Cited by 128
Self-citationSaussez, S., Lorfevre, F., Lequeux, T., Laurent, G., Chantrain, G., Vertongen, F., Toubeau, G., Decaestecker, C., & Robert Kiss, A. (2007) · Oral Oncology · doi:10.1016/j.oraloncology.2006.12.014 · Cited by 125
Kadrofske, M. M., Openo, K. P., & Wang, J. L. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0447 · Cited by 123
The immunological potential of galectin-1 and -3
Dhirapong, A., Lleò, A., Leung, P. S. C., Gershwin, M. E., & Liu, F. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.11.009 · Cited by 120
Okamura, D. M., Pasichnyk, K., López-Guisa, J. M., Collins, S., Hsu, D. K., Liu, F., & Eddy, A. A. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00326.2010 · Cited by 103
Serum level of galectin-3 in human bladder cancer
Sakaki, M., Oka, N., Nakanishi, R., Yamaguchi, K., Fukumori, T., & Kanayama, H. (2008) · The Journal of Medical Investigation · doi:10.2152/jmi.55.127 · Cited by 71
Galectin‐3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells
Arar, C., Gaudin, J., Capron, L., & Legrand, A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00683-8 · Cited by 67
Udelson, J. E., & Konstam, M. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.01.009 · Cited by 50
Lee, J., Kang, S. W., Song, J. K., Park, J. J., Bae, Y.-D., Ey, L., Lee, E. B., & Song, Y. W. (2007) · PubMed · Cited by 49
Wang, Y., Balan, V., & Raz, A. (2008) · CRC Press eBooks · doi:10.1201/9781420006971.pt4 · Cited by 33
Cited by
Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community
Ho, J. E., Liu, C., Lyass, A., Courchesne, P., Pencina, M. J., Vasan, R. S., Larson, M. G., & Levy, D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.053 · Cited by 589
Yu, L., Ruifrok, W. P. T., Meissner, M., Bos, E. M., van Goor, H., Sanjabi, B., van der Harst, P., Pitt, B., Goldstein, I. J., Koerts, J. A., et al. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.971168 · Cited by 435
Self-citationVascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications
Harvey, A., Montezano, A. C., Lopes, R. A., Rios, F., & Touyz, R. M. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.02.070 · Cited by 383
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G., Bellotti, C., Salehi, L., & Ricci, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020379 · Cited by 377
Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update
Suthahar, N., Meijers, W. C., Silljé, H. H. W., Ho, J. E., Liu, F.-T., & de Boer, R. A. (2018) · Theranostics · doi:10.7150/thno.22196 · Cited by 309
Self-citation
Metadata
- Authors
- de Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller Kobold, A. C., van Gilst, W. H., Hillege, H. L., Bakker, S. J. L., & van der Harst, P.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2011-11-18
- Volume
- 272
- Issue
- 1
- Pages
- 55-64
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2142280282
- Cited by
- 376
- References
- 33
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.